Skip to main content
PepStack
Wiki · Profile

Tesamorelin

Egrifta · TH9507

GH SecretagogueApproved
From$3.90/mgCompare prices
MW
5136g/mol
Formula
C221H366N72O67S

Tesamorelin, a growth hormone-releasing factor analogue, is classified as a therapeutic peptide and was developed for the management of abdominal fat accumulation associated with HIV-related lipodystrophy. Researchers primarily study tesamorelin for its effects on body composition and metabolic parameters in individuals living with HIV. Key findings from clinical trials indicate that tesamorelin is associated with significant reductions in visceral fat and improvements in hepatic fat content without exacerbating glycemic control. Current research continues to explore its efficacy and safety, particularly in populations using integrase inhibitors, highlighting the need for further investigation into its broader applications in metabolic health.

Chemical Profile

Chemical Profile

Chemical structure
Chemical Structure
FormulaC221H366N72O67S
Molecular Weight5136 g/mol
CAS Number218949-48-5
PubChem CID16137828

Half-Life

SCSubcutaneous

~4 hours

INIntranasal

Not applicable

POOral

Poor bioavailability

Subcutaneous administration is the primary route due to its effective bioavailability.

Mechanism

Mechanism of Action

Tesamorelin is a growth hormone-releasing hormone (GHRH) analogue that binds to GHRH receptors on pituitary somatotrophs, stimulating the release of endogenous growth hormone (GH). This leads to increased levels of insulin-like growth factor 1 (IGF-1) and activation of the GH/IGF-1 signaling pathway, which promotes lipolysis and reduces visceral adipose tissue. While the precise mechanisms underlying its effects on body composition are not fully understood, it is known to influence metabolic processes related to fat distribution and energy homeostasis.

Research

46 Research Publications

1,383

Total Citations

25

Human/RCT

2.6

Avg. Influence

2024

Latest

Sort
Filter
#01

Metabolic effects of a growth hormone-releasing factor in patients with HIV.

HumanInfluence6.0
186
The study demonstrated that tesamorelin significantly decreased visceral adipose tissue and improved lipid profiles in HIV-infected patients with abdominal fat accumulation over 26 weeks.
2 mgonce daily(human)12 months2 mgs.c.(human)daily for 26 weeks1 or 2 mgsubcutaneous(human)daily during 14 consecutive days
PubMed
#02

Cardiovascular risk and dyslipidemia among persons living with HIV: a review.

ReviewInfluence8.0
129
Researchers observed that lifestyle modifications and pharmacological interventions, including tesamorelin, are critical for managing cardiovascular risk and dyslipidemia in HIV-infected individuals.
2 mgonce daily(human)12 months2 mgs.c.(human)daily for 26 weeks1 or 2 mgsubcutaneous(human)daily during 14 consecutive days
PubMed
#03

Growth hormone in the aging male.

ReviewInfluence6.0
110
The review indicated that tesamorelin may restore normal growth hormone pulsatility and improve metabolic parameters in aging males.
2 mgonce daily(human)12 months2 mgs.c.(human)daily for 26 weeks1 or 2 mgsubcutaneous(human)daily during 14 consecutive days
PubMed
#04

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.

HumanInfluence2.0
88
The study demonstrated that tesamorelin significantly reduced visceral adipose tissue and improved lipid profiles in HIV patients over 52 weeks without significant changes in glucose parameters.
2 mgonce daily(human)12 months2 mgs.c.(human)daily for 26 weeks1 or 2 mgsubcutaneous(human)daily during 14 consecutive days
PubMed
#05

Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.

Human
78
The study demonstrated that tesamorelin significantly reduced both visceral and liver fat in HIV-infected patients over six months, indicating its potential metabolic benefits.
2 mgonce daily(human)12 months2 mgs.c.(human)daily for 26 weeks1 or 2 mgsubcutaneous(human)daily during 14 consecutive days
PubMed
#06

Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.

HumanInfluence5.0
75
The study demonstrated that tesamorelin reduces visceral fat by approximately 18% and improves body image distress in HIV-infected patients without significant side effects or glucose perturbation.
2 mgonce daily(human)12 months2 mgs.c.(human)daily for 26 weeks1 or 2 mgsubcutaneous(human)daily during 14 consecutive days
PubMed
#07

How to diagnose a lipodystrophy syndrome.

ReviewInfluence1.0
67
The study demonstrated that tesamorelin is effective in managing metabolic syndrome in HIV patients, particularly in reducing visceral fat accumulation.
2 mgonce daily(human)12 months2 mgs.c.(human)daily for 26 weeks1 or 2 mgsubcutaneous(human)daily during 14 consecutive days
PubMed
#08

Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.

HumanInfluence5.0
66
The study demonstrated that tesamorelin significantly reduced hepatic fat fraction in HIV-infected patients with non-alcoholic fatty liver disease compared to placebo.
2 mgonce daily(human)12 months2 mgs.c.(human)daily for 26 weeks1 or 2 mgsubcutaneous(human)daily during 14 consecutive days
PubMed
#09

Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.

HumanInfluence1.0
60
The study demonstrated that tesamorelin was well tolerated and resulted in sustained reductions in visceral adipose tissue and triglycerides over 52 weeks in HIV patients.
2 mgonce daily(human)12 months2 mgs.c.(human)daily for 26 weeks1 or 2 mgsubcutaneous(human)daily during 14 consecutive days
PubMed
#10

Peptide Ligation at High Dilution via Reductive Diselenide-Selenoester Ligation.

In Vitro
53
Researchers observed that the reductive diselenide-selenoester ligation method enables efficient synthesis of the lipopeptide tesamorelin and lipidated variants of phospholemman, enhancing their biological activity.
2 mgonce daily(human)12 months2 mgs.c.(human)daily for 26 weeks1 or 2 mgsubcutaneous(human)daily during 14 consecutive days
PubMed
Safety

Safety & Handling

Research Gaps

There is a lack of robust clinical trials evaluating the efficacy of tesamorelin in orthopaedic applications, as its current evidence is limited to its use in HIV-related lipodystrophy. Additionally, the long-term effects of tesamorelin on metabolic health and tissue regeneration in non-HIV populations remain unknown, and the specific mechanisms by which tesamorelin may influence musculoskeletal healing are not well understood.

Solubility

Tesamorelin is soluble in water and commonly reconstituted in bacteriostatic water for injection.

Storage & Handling

Lyophilized

Stable for 2+ years at -20°C, 12 months at 4°C

Reconstituted

Use within 14 days when refrigerated at 4°C

Avoid

Avoid repeated freeze-thaw cycles, direct light

Solvent

Bacteriostatic water or sterile saline recommended

Safety information is derived from published research and may not reflect all known risks. This is not medical advice.

Legal Status

Legal Status

🇩🇪DE

Not approved as a medicinal product. Not a controlled substance. Sale as research chemical is a legal grey area.

🇺🇸US

Approved by the FDA for the treatment of HIV-associated lipodystrophy. Not scheduled by the DEA.

🇦🇺AU

Data limited

🇬🇧UK

Data limited

Legal status information is provided for general reference only and may not reflect the most current regulatory changes. Always verify with official government sources before making any decisions.

Community Insights

Community Insights

Publications per Year

47 total
1
06
1
07
1
08
1
09
2
10
6
11
3
12
2
13
2
14
3
15
5
17
1
18
2
19
1
20
3
21
2
22
1
24
2
25
8
26
Pricing

Price Comparison

  • BESTRetaOneLabsUS
    10mg
    $39.00
    Price/mg
    $3.90/mg
    View
  • Alpha PeptidesUS
    10mg
    $39.99
    $35.99
    Price/mg
    $4.00$3.60/mg
    View−10% · PEPSTACK10
  • RetaOneLabsUS
    20mg
    $92.00
    Price/mg
    $4.60/mg
    View
  • Welli LabsUS
    10mg
    $49.99
    Price/mg
    $5.00/mg
    View
  • Soma ChemsUS
    10mg
    $49.99
    Price/mg
    $5.00/mg
    View

Top 5 of 50 offers from 54 vendors. Prices updated daily.

See all Tesamorelin prices
Mechanism

Tools

Reconstitution Calculator

Calculate reconstitution volumes for Tesamorelin

Serum Level Visualizer

Visualize Tesamorelin serum levels over time

Mechanism

Related Peptides

SermorelinGHRP-2MK-677GHRP-6HexarelinCJC-1295

Track Tesamorelin in PepStack

Log your research cycles, set reminders and visualize serum levels.

Download on theApp StoreGet it onGoogle Play
Legal Disclaimer

This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer